Nephro-Urology Monthly

Published by: Kowsar

Comparison of Hemoglobin Levels Before and After Hemodialysis and Their Effects on Erythropoietin Dosing and Cost

Mohammad Mahdi Sagheb 1 , Mohammad Amin Fallahzadeh 1 , * , Alireza Moaref 2 , Mohammad Hossein Fallahzadeh 1 and Banafshe Dormanesh 3
Authors Information
1 Shiraz Nephrourology Research Center, Shiraz University of Medical Sciences, Shiraz, IR Iran
2 Department of Cardiology, Shiraz University of Medical Sciences, Shiraz, IR Iran
3 Department of Pediatrics, AJA University of Medical Sciences, Tehran, IR Iran
Article information
  • Nephro-Urology Monthly: July 01, 2016, 8 (4); e38495
  • Published Online: June 29, 2016
  • Article Type: Research Article
  • Received: April 15, 2016
  • Revised: May 18, 2016
  • Accepted: May 30, 2016
  • DOI: 10.5812/numonthly.38495

To Cite: Sagheb M M, Fallahzadeh M A, Moaref A, Fallahzadeh M H, Dormanesh B. Comparison of Hemoglobin Levels Before and After Hemodialysis and Their Effects on Erythropoietin Dosing and Cost, Nephro-Urol Mon. 2016 ; 8(4):e38495. doi: 10.5812/numonthly.38495.

Abstract
Copyright © 2016, Nephrology and Urology Research Center. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Footnotes
References
  • 1. Hayat A, Haria D, Salifu MO. Erythropoietin stimulating agents in the management of anemia of chronic kidney disease. Patient Prefer Adherence. 2008; 2: 195-200[PubMed]
  • 2. Babitt JL, Lin HY. Mechanisms of anemia in CKD. J Am Soc Nephrol. 2012; 23(10): 1631-4[DOI][PubMed]
  • 3. Аhemii К. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney International. 2012; 2(4): 279-335
  • 4. Schmid H, Schiffl H. Erythropoiesis stimulating agents and anaemia of end-stage renal disease. Cardiovasc Hematol Agents Med Chem. 2010; 8(3): 164-72[PubMed]
  • 5. Gaweda AE, Nathanson BH, Jacobs AA, Aronoff GR, Germain MJ, Brier ME. Determining optimum hemoglobin sampling for anemia management from every-treatment data. Clin J Am Soc Nephrol. 2010; 5(11): 1939-45[DOI][PubMed]
  • 6. Parfrey PS, Wish T. Quality of life in CKD patients treated with erythropoiesis-stimulating agents. Am J Kidney Dis. 2010; 55(3): 423-5[DOI][PubMed]
  • 7. Parfrey PS, Foley RN, Wittreich BH, Sullivan DJ, Zagari MJ, Frei D. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol. 2005; 16(7): 2180-9[DOI][PubMed]
  • 8. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009; 361(21): 2019-32[DOI][PubMed]
  • 9. Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Tonelli M, Garg AX, et al. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med. 2010; 153(1): 23-33[DOI][PubMed]
  • 10. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998; 339(9): 584-90[DOI][PubMed]
  • 11. Vlassopoulos D, Sonikian M, Dardioti V, Hadjiconstantinou V. Target haematocrit during erythropoietin treatment in dialysis patients. Which value is 'true-functional haematocrit'? Nephrol Dial Transplant. 1999; 14(5): 1340-1[PubMed]
  • 12. Bellizzi V, Minutolo R, Terracciano V, Iodice C, Giannattasio P, De Nicola L, et al. Influence of the cyclic variation of hydration status on hemoglobin levels in hemodialysis patients. Am J Kidney Dis. 2002; 40(3): 549-55[DOI][PubMed]
  • 13. Movilli E, Pertica N, Camerini C, Cancarini GC, Brunori G, Scolari F, et al. Predialysis versus postdialysis hematocrit evaluation during erythropoietin therapy. Am J Kidney Dis. 2002; 39(4): 850-3[DOI][PubMed]
  • 14. Castillo N, Garcia-Garcia P, Rivero A, Jimenez-Sosa A, Macia M, Getino MA, et al. Should we adjust erythropoiesis-stimulating agent dosage to postdialysis hemoglobin levels? A pilot study. BMC Nephrol. 2012; 13: 60[DOI][PubMed]
  • 15. Recombinant Human Erythropoietin Alfa. 2016;
  • 16. Aghighi M, Heidary Rouchi A, Zamyadi M, Mahdavi-Mazdeh M, Rajolani H, Ahrabi S, et al. Dialysis in Iran. Iran J Kidney Dis. 2008; 2(1): 11-5[PubMed]
  • 17. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006; 355(20): 2085-98[DOI][PubMed]
  • 18. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006; 355(20): 2071-84[DOI][PubMed]
  • 19. Phrommintikul A, Haas SJ, Elsik M, Krum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet. 2007; 369(9559): 381-8[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments